Back

First real-world assessment of the extravascular implantable cardioverter-defibrillator: periprocedural outcomes from the Enlighten post-market study and comparison to a pre-market cohort

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Implantable cardioverter-defibrillator therapy Device Treatment EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Lucas Boersma

St Antonius Hospital, Nieuwegein (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Comparison of newly detected atrial high-rate episodes incidence in single-lead ICDs with a floating atrial dipole and dual-chamber ICDs: a propensity score-matched analysis from the HMEA project
Doctor G. Mitacchione (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
Single- versus dual-chamber ICD discriminators for tachyarrhythmia detection: a remote monitoring based, single-center study
Doctor F. Gausz (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Implantable cardioverter-defibrillator therapies in primary prevention are not decreased in a contemporary cohort: insights from long-term follow-up
Doctor I. Ferreira Neves (Lisboa, PT)
Abstract Slides Video
Presentation thumbnail
In silico modeling of cardiac defibrillation with novel deep septal ICD leads
Doctor G. Imnadze (Bad Oeynhausen, DE)
Abstract Slides Video
Presentation thumbnail
Evaluating subcutaneous implantable cardioverter defibrillators in hypertrophic cardiomyopathy: fewer complications without increased therapies
Mr C. Monkhouse (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Implantable cardioverter-defibrillator therapy

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Extravascular implantable cardioverter-defibrillator therapy: real-world clinical results
thumbnail
Congress Session
DIRECTing the future: how new cardiac technologies empower patient outcomes
thumbnail
Congress Presentation
Six-month safety and therapy efficacy of the extravascular implantable defibrillator in those 65 years or older: real-world results from the enlighten study post approval registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources